Sun Pharma Q4 net up 23 percent, beats estimate
MUMBAI (Reuters) - Sun Pharmaceutical Industries(SUN.NS) reported a 23.4 percent rise in quarterly net profit beating market estimates, and India's top drugmaker by market value also announced a bonus share issue.
The Mumbai-based company said consolidated net profit rose to 10.12 billion rupees for the fourth quarter ended March 31, compared with 8.2 billion rupees a year earlier. Sales rose 31.8 percent to 30.71 billion rupees.
Analysts, on an average, had expected the company to post net profit of 9.07 billion rupees on net sales of 29.85 billion rupees, according to Thomson Reuters I/B/E/S.
The company also announced a one-for-one issue of bonus shares.
Shares of Sun Pharma, which has a market value of about $18.81 billion, fell 1.72 percent to 996.25 rupees on Tuesday, while the broader market gained 0.65 percent on the day. The stock has risen nearly 38 percent this year outperforming the benchmark index which has gained about 4 percent.
(Reporting by Kaustubh Kulkarni; Editing by Anand Basu)
- Tweet this
- Share this
- Digg this
- EXCLUSIVE - Apple iPhone 6 screen snag leaves supply chain scrambling
- U.S. strikes have slowed Iraq militants but not weakened them - Pentagon
- Arvind Subramanian likely to be chief econ adviser
- UPDATE 3-Dynegy cuts exposure to wholesale power with deals worth $6.25 bln
- Nifty touches record high; software stocks gain
More than 70 percent of Indians are satisfied with the leadership of Prime Minister Narendra Modi since he took office nearly three months ago, an opinion poll showed, seeing in him the best hope to put the economy back on track. Full Article
India to hike iron ore royalty, miners may struggle to pass on extra cost. Full Article